Cowen and Company reaffirmed their buy rating on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a research note published on Tuesday morning.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Myovant Sciences from a hold rating to a sell rating in a report on Wednesday, June 21st. Evercore ISI initiated coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an outperform rating on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $18.20.

Myovant Sciences (NASDAQ:MYOV) traded up 1.21% during mid-day trading on Tuesday, hitting $15.06. The company had a trading volume of 5,994 shares. The firm’s market capitalization is $916.31 million. The company has a 50-day moving average price of $13.46 and a 200 day moving average price of $13.46. Myovant Sciences has a 12 month low of $10.25 and a 12 month high of $18.85.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/myovant-sciences-ltd-myov-receives-buy-rating-from-cowen-and-company/1607430.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management LLC raised its position in Myovant Sciences by 56.6% during the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after acquiring an additional 848,422 shares during the period. Eventide Asset Management LLC acquired a new stake in shares of Myovant Sciences in the first quarter valued at about $3,463,000. Emory University acquired a new stake in shares of Myovant Sciences in the second quarter valued at about $1,512,000. Susquehanna International Group LLP acquired a new stake in shares of Myovant Sciences in the second quarter valued at about $648,000. Finally, LMR Partners LLP acquired a new stake in shares of Myovant Sciences in the second quarter valued at about $320,000.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.